Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
Zanghì A, Borriello G, Bonavita S, Fantozzi R, Signoriello E, Barone S, Abbadessa G, Cellerino M, Ziccone V, Miele G, Lus G, Valentino P, Bucello S, Inglese M, Centonze D, Avolio C, D'Amico E. Zanghì A, et al. Among authors: avolio c. J Neurol. 2024 Jul;271(7):4495-4502. doi: 10.1007/s00415-024-12360-x. Epub 2024 May 4. J Neurol. 2024. PMID: 38704488 Free PMC article.
[Registers as central real world data source: the experience of the Italian Multiple Sclerosis and Related Disorders Register].
Ponzio M, Battaglia MA, Trojano M, Salivetto M, D'Ettorre A, Corrado D, Paletta P, Lepore V, Mosconi P; Comitato Scientifico del Registro Italiano Sclerosi Multipla e Patologie Correlate; Rete dei centri del Registro Italiano Sclerosi Multipla e Patologie Correlate; Rete degli assistenti di ricerca del Registro Italiano Sclerosi Multipla e Patologie Correlate. Ponzio M, et al. Epidemiol Prev. 2024 Jul-Oct;48(4-5):In press. doi: 10.19191/EP24.4-5.A734.074. Epidemiol Prev. 2024. PMID: 39329242 Italian.
Myeloid-derived Suppressor Cells and Multiple Sclerosis.
Zanghì A, Di Filippo PS, Avolio C, D'Amico E. Zanghì A, et al. Among authors: avolio c. Curr Neuropharmacol. 2024 Jul 10. doi: 10.2174/1570159X22999240710142942. Online ahead of print. Curr Neuropharmacol. 2024. PMID: 38988152
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study.
Chisari CG, Aguglia U, Amato MP, Bergamaschi R, Bertolotto A, Bonavita S, Morra VB, Cavalla P, Cocco E, Conte A, Cottone S, De Luca G, Di Sapio A, Filippi M, Gallo A, Gasperini C, Granella F, Lus G, Maimone D, Maniscalco GT, Marfia G, Moiola L, Paolicelli D, Pesci I, Ragonese P, Rovaris M, Salemi G, Solaro C, Totaro R, Trojano M, Vianello M, Zaffaroni M, Lepore V, Patti F; Italian MS Register Study Group. Chisari CG, et al. Neurotherapeutics. 2024 Jul;21(4):e00363. doi: 10.1016/j.neurot.2024.e00363. Epub 2024 May 7. Neurotherapeutics. 2024. PMID: 38714462 Free PMC article.
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries.
Sharmin S, Roos I, Malpas CB, Iaffaldano P, Simone M, Filippi M, Kubala Havrdova E, Ozakbas S, Brescia Morra V, Alroughani R, Zaffaroni M, Patti F, Eichau S, Salemi G, Di Sapio A, Inglese M, Portaccio E, Trojano M, Amato MP, Kalincik T; Writing Group; Italian Multiple Sclerosis and Related Disorders Register and MSBase Study Group. Sharmin S, et al. Lancet Child Adolesc Health. 2024 May;8(5):348-357. doi: 10.1016/S2352-4642(24)00047-6. Epub 2024 Mar 25. Lancet Child Adolesc Health. 2024. PMID: 38547883
105 results